J. David Hansen
President, CEO and Chairman
David Hansen serves as the President, Chief Executive Officer, and Chairman of the Board of Directors and, prior to the merger with Telik, Inc. on July 8, 2014 (the "Merger"), served as President, Chief Executive Officer, and Chairman of the Board of Directors of MabVax Therapeutics, Inc. after co-founding the Company in 2006. Mr. Hansen is an experienced biopharmaceutical executive with more than 30 years of industry experience. He has held senior management roles in both private start-up companies as well as small to mid-sized public companies. His senior level experience includes executive management, finance and accounting, corporate development, and sales and marketing. During his career, he has executed a wide variety of in and out licensing agreements, research and development collaborations, joint ventures, divestitures, and acquisitions. He has developed expertise in the therapeutic areas of immunology, oncology, and infectious disease. He gained executive management experience at several life sciences companies prior to co-founding the Company that make him particularly suited for his leadership role in the Company. For example, he was a corporate officer of Avanir Pharmaceuticals where he held the titles of Vice President of Commercial Development, Senior Vice President of Corporate Development, and President and Chief Operations Officer of the Avanir Subsidiary Xenerex Biosciences. Prior to Avanir, he served in multiple roles at Dura Pharmaceuticals including National Sales Director, Director of Marketing, and Director of Business Development. He has additional management experience with Merck & Co. (Schering-Plough), Key Pharmaceuticals, and Bristol Myers Squibb. The Company believes that Mr. Hansen's extensive experience with public and private pharmaceutical companies in a leadership role qualifies him to serve as Chairman of the Board of Directors and as President and Chief Executive Officer.
Paul F. Resnick
Vice President and Chief Business Officer
Paul F. Resnick, M.D., M.B.A. serves as Vice President and Chief Business Officer. Dr. Resnick joined the Company in March 2016. January 2013 to March 2016, Dr. Resnick was Senior Vice President, Business Development for Juventas Therapeutics, where he was responsible for business and commercial strategy and working with executive management overseeing corporate clinical development and financial and business strategies. From February 2012 to December 2012, he was an advisor for several companies in the life sciences area. From January 2008 to January 2012, he was Vice President of Business Development for Intellikine, Inc., responsible for managing alliances and leading the business development strategy that resulted in securing the acquisition by Takeda Pharmaceuticals. During the course of his career, he has been able to gain extensive experience, qualifying him for his executive leadership role in business development for the Company. For example, he has held Senior Director positions for Worldwide Business Development and for Strategic Alliances at Pfizer Inc., where he was responsible for networking with leaders from biotechnology companies, universities and research institutions to gain early insights into emerging technologies and for leading technical and business diligence, negotiations and alliance management of science and technology initiatives for Pfizer's Biotechnology and Bio-innovation Center. Prior to Pfizer, Dr. Resnick held Director and Senior Director positions at Rinat Neuroscience (acquired by Pfizer), Intermune, Inc. and Roche Pharmaceuticals.
Dr. Resnick holds an M.D. from the Medical College of Wisconsin and an M.B.A. from the Wharton School of the University of Pennsylvania.
Gregory P. Hanson
Chief Financial Officer
Gregory P. Hanson, C.M.A., M.B.A. serves as Chief Financial Officer, and prior to the Merger served as Chief Financial Officer of MabVax Therapeutics, Inc. from February of 2014. Mr. Hanson has over 30 years serving as CFO/financial executive of both public and private biotech and hi tech companies. From January 2008 to February 2014, he was Managing Director of First Cornerstone, a board and management advisory service to companies and executives in the areas of international corporate development, financing strategies, commercialization of technologies and products, and M&A advisory service. Since November 2009, he has served as Advisory Board Member of Menon International, Inc. involved in commercialization of biosensor devices and assays as well as renewable products. Since October 2011, he has served on the Life Sciences Advisory Board of Brinson Patrick Securities, a boutique investment bank. He also serves as mentor and confidential advisor to several other tech and life sciences companies. He was previously President and 9-year Member of the Board of Directors of San Diego Financial Executives International (FEI), and a member of the Capital Formation Committee at BIOCOM from 2011. Earlier in his career, he was able to gain substantial executive management experience that helped qualify him in his role as Chief Financial Officer. For example, he served as Senior Vice President of Brinson Patrick Securities, where he opened up the San Diego branch and introduced at-the-market financing strategies to public life sciences companies. Prior to Brinson Patrick Securities, he served as Senior Vice President and Chief Financial Officer of Mast Therapeutics (MSTX-NYSE MKT), and prior to Mast Therapeutics was Vice President and CFO, Chief Accounting Officer, Compliance Officer and Corporate Secretary of Avanir Pharmaceuticals, Inc. (acquired by Otsuka Holdings Co., Ltd.), the developer of the cold sore product Abreva™, and Neudexta™, for the treatment of Pseudobulbar Affect, a central nervous system disorder. During the course of his career, he has completed approximately $1 billion in financing, licensing and partnering arrangements. Mr. Hanson was a founding and 6-year member of the Small Business Advisory Committee to the Financial Accounting Standards Board, and has spoken at various national conferences, industry organizations and panels on financing strategy and mergers and acquisitions, and twice spoken to the SEC';s Committee on Improvements to Financial Reporting.
Mr. Hanson has passed the examination for Certified Public Accountants and is a Certified Management Accountant. He holds an M.B.A. with distinction from the University of Michigan, and a B.S. in Mechanical Engineering from Kansas State University. Since 2008, he has maintained Series 7 & Series 63 securities licenses.
Wolfgang W. Scholz
Vice President of Antibody Discovery
Wolfgang W. Scholz, Ph.D. serves as Vice President of Antibody Discovery and, prior to the Merger, in 2006, was a co-founder and the Vice President of Antibody Discovery of MabVax Therapeutics, Inc. Dr. Scholz has extensive drug discovery experience in multiple therapeutic categories and has collaborated with major pharmaceutical companies on several projects. As part of the experience that helps him qualify for his leadership role in antibody discovery at the Company, he was Senior Director at Avanir Pharmaceuticals, where he led research and development efforts for eight years, and was a co-founder of Xenerex Biosciences, a subsidiary owned by Avanir Pharmaceuticals. Under his leadership, the antibody discovery group at Xenerex developed human monoclonal antibodies to multiple infectious disease targets using in vitro and SCID mouse technologies. One antibody (AVP-21D9) was successfully out-licensed and recently passed Phase I safety testing. Prior to Avanir, he held positions with increasing responsibilities at Tanabe Research Laboratories. Over his career His work has been funded by multiple grants from the National Institute for Allergy and Infectious Diseases. He is the principal investigator on multiple National Cancer Institute grants received by MabVax totaling almost $5 million. Dr. Scholz is an inventor on three pending and three issued antibody patents, three issued small molecule patents, and author on 34 peer-reviewed publications.
Dr. Scholz earned his Ph.D. in Microbiology and Immunology from the University of Kiel, Germany in 1985 and completed his postdoctoral training at The Scripps Research Institute, La Jolla. The Company believes his experience in antibody discovery and institutional knowledge of the Company's vaccine programs qualifies him to serve as Vice President of Antibody Discovery.
Paul W. Maffuid, Ph.D.
Executive VP of Research and Development
Paul W. Maffuid, Ph.D. serves as Executive Vice President of Research and Development. Dr. Maffuid joined the Company in July 2014 as Vice President of Pharmaceutical Operations. He is an experienced biopharmaceutical executive with more than 30 years of pharmaceutical industry experience. His management experience includes global pharmaceutical organizations, developing biotechnology companies and contract development and manufacturing organizations. His senior level management experience includes leadership for product development, manufacturing and drug disposition. Throughout his career, his organizations were integral for research and development activities and represented by regulatory filings for biopharmaceuticals and small molecule therapeutics indicated for oncology, diabetes, CNS disorders and obesity. Prior to joining the Company, he gained executive management experience at several life sciences companies, which makes him particularly suited and qualified for his leadership role in the Company. From 2011 to June 2014, he served as Executive Vice President, Pharma Operations for AAIPharma Services Corporation and was a member of the Executive Team that transformed a declining business into a leading provider of integrated drug development services. His responsibilities included formulation, manufacturing and analytical services for clients developing biologic and small molecule therapeutics. Prior to joining AAIPharma he was the founder and President of Biopharmalogics, Inc., a consulting company supporting the development of pharmaceutical products from 2008 to 2011. Earlier in his career, he was Senior Vice President of Operations at Irvine Pharmaceutical Services, Inc., and Vice President of Pharmaceutical Development for Arena Pharmaceuticals. While at Arena Pharmaceuticals, he was a member of the executive management team, responsible for drug product and drug disposition research and development operations, and led the design and construction of a cGMP compliant pilot manufacturing facility. Dr. Maffuid's management experience also includes Amylin Pharmaceuticals, Magellan Laboratories and Glaxo Research Institute (currently GSK).
Philip O. Livingston, M.D.
Chief Science Officer
Philip O. Livingston, M.D. serves as a member of the Board of Directors and Chief Science Officer and, prior to the Merger, served as a member of the Board of Directors and Chief Science Officer of MabVax Therapeutics, Inc. from 2012. Dr. Livingston received his M.D. degree from Harvard Medical School, was Professor of Medicine in the Joan and Sanford Weill Medical College at Cornell University, and also Attending Physician and Member in Memorial Sloan-Kettering Cancer Center (MSKCC), where he treated melanoma patients and ran the Cancer Vaccinology Laboratory research lab for over 30 years until his retirement from MSKCC on October 1, 2011. HIs research focused on identification of suitable targets for immunotherapy of a variety of cancers, construction of polyvalent conjugate vaccines specifically designed to augment antibody responses against these targets, and identification of optimal immunological adjuvants to further augment the potency of these vaccines. He has more than 150 publications and four issued and three pending patents concerning cancer vaccines. Recently, he helped establish MabVax Therapeutics, Inc., and another biotech company, Adjuvance Technologies, Inc. MabVax Inc. supports two randomized Phase II trials with these MSK polyvalent vaccines and establishment of human monoclonal antibodies from the blood of immunized patients. The Company believes that Dr. Livingston's extensive expertise in immunotherapy qualifies him to serve as a member of the Board of Directors and Chief Science Officer.